Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 40.35M P/E - EPS this Y 43.00% Ern Qtrly Grth -
Income -24.41M Forward P/E -1.95 EPS next Y 72.60% 50D Avg Chg -15.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 5.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -59.00%
Recommedations 2.00 Quick Ratio 3.19 Shares Outstanding 94.36M 52W Low Chg 193.00%
Insider Own 6.73% ROA -53.37% Shares Float 79.98M Beta 2.33
Inst Own 30.24% ROE -121.76% Shares Shorted/Prior 384.94K/1.84M Price 1.17
Gross Margin - Profit Margin - Avg. Volume 182,351 Target Price 5.08
Oper. Margin - Earnings Date - Volume 52,112 Change 0.86%
About Unicycive Therapeutics, Inc.

Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.

Unicycive Therapeutics, Inc. News
11/21/24 Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
11/13/24 Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
11/11/24 Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
10/28/24 Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
10/16/24 Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
10/16/24 Results of Phase I trial shed positive light on UNI-494 for acute kidney injury
10/14/24 Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
10/09/24 Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
09/24/24 Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
09/20/24 Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
09/16/24 Life Sciences Virtual Investor Forum Agenda Announced for September 19th
09/16/24 Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
09/05/24 Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
09/03/24 Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
08/26/24 Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
08/21/24 Companies Like Unicycive Therapeutics (NASDAQ:UNCY) Are In A Position To Invest In Growth
08/14/24 Unicycive Announces Second Quarter 2024 Financial Results and Provides Business Update
07/17/24 Unicycive Therapeutics Granted Patent on UNI-494 to Treat Acute Kidney Injury by the United States Patent and Trademark Office (USPTO)
07/11/24 Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
07/10/24 Unicycive Therapeutics Announces Initial Positive Patient Satisfaction Findings from Pivotal Clinical Trial of Oxylanthanum Carbonate (OLC)
UNCY Chatroom

User Image B2iDigital Posted - 4 hours ago

The team at B2i Digital is pleased to share that our Featured Company, Unicycive Therapeutics (Nasdaq: $UNCY) (https://b2idigital.com/unicycive), a clinical-stage biotechnology company focused on kidney disease, will participate in two investor conferences this December. Upcoming Conferences: NOBLE Capital Markets 20th Annual Emerging Growth Equity Conference https://nobleconference.com/ Date: Tuesday, December 3, 2024 Time: 3:00 PM ET Location: Boca Raton, FL Piper Sandler 36th Annual Healthcare Conference https://www.pipersandler.com/conferences-and-events?sectors=518 Event: Fireside Chat Date: Thursday, December 5, 2024 Time: 12:30 PM ET Location: New York, NY Live and archived webcasts of these events will be available under the Events and Presentations section of Unicycive’s IR website. To schedule a 1-on-1 meeting with management, contact your Noble Capital Markets or Piper Sandler representative. The complete news release about the company’s participation in these two conferences is available at https://ir.unicycive.com/news/detail/90/unicycive-therapeutics-to-participate-in-two-upcoming B2i Digital acknowledges the continued diligence of Dr. Shalabh Gupta, MD and his dedicated management team, including CFO John Townsend, EVP Doug Jermasek, EVP Pramod Gupta, Dr. Atul Khare, Ph.D., M.B.A., and Dr. Guru Reddy, in their mission to address unmet needs in kidney disease treatment. Please visit Unicycive (https://unicycive.com/) and B2i Digital (https://b2idigital.com/) to learn more. #Unicycive #UNCY #B2iDigital #InvestorConference #KidneyDisease #Biotech DISCLAIMER: B2i Digital’s CEO, David Shapiro, owns 60,000 shares of unrestricted UNCY stock as of November 21, 2024. This post is not intended to solicit the sale of UNCY or any security, and it is not intended to offer any opinion on UNCY as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the full disclaimer in the Risks and Disclosures section of https://b2idigital.com/unicycive.

User Image ThisWi11hurt Posted - 6 hours ago

$NUWE loaded up again 1.21 $TNXP $UNCY $TPST

User Image StockAuthority Posted - 12 hours ago

$SNSE red to green coming here, these bios tend to dip in am, then run in PM. Who else remembers that with $UNCY as we marched up 150% off bottom? every day, great buys in AM then rips in afternoon.

User Image KING_OF_BIO Posted - 13 hours ago

$UNCY Chart is looking clear for takeoff - I'm in :)

User Image ROMEO44 Posted - 16 hours ago

$SWTX $UNCY $CTCX $CDT

User Image StockMasterHere Posted - 17 hours ago

$CDT $0.25 Today, Massive buying by insiders, 5 form 4 filed yesterday after market close. LFG and open at $0.15 $UNCY $SWTX $CTCX

User Image Warewolf Posted - 1 day ago

$UNCY Trust the process.

User Image Charli_with_an_I Posted - 1 day ago

@GREGORYARCHANGEL love it! $mcrb $UNCY and $ALT have been fun today!

User Image DouglasJanes2025 Posted - 1 day ago

$UNCY booooring. Wake me up at $2!

User Image Kingesco626 Posted - 1 day ago

$UNCY

User Image Smesic Posted - 1 day ago

$UNCY bio stocks are on 🔥 today!

User Image TaZMaNiDEviL Posted - 1 day ago

$UNCY halfway there 😊

User Image Tonyboner Posted - 1 day ago

$UNCY Added 20k @ 48c

User Image MikeProZ Posted - 1 day ago

$UNCY Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update

User Image Smesic Posted - 1 day ago

$SNSE $VISL $UNCY let’s have a great day today! 🙏📈

User Image Mikem239 Posted - 1 day ago

$UNCY I bought 10,000 more at .43. I’m a believer. GLTA

User Image Lbgodfrey Posted - 2 days ago

$UNCY

User Image KP81 Posted - 2 days ago

$UNCY look at those curls . daily looking good. Bet we retest .5 and retest .6 gap

User Image Grelada Posted - 2 days ago

$UNCY

User Image SmallCapGrowth Posted - 2 days ago

$UNCY Unicycive Announces Third - BREAKOUTS..RUNNERS AND HOT PENNIES https://investorshangout.com/post/view?id=6730543 @chazzsheen3

User Image SmallCapGrowth Posted - 2 days ago

$UNCY Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis https://finance.yahoo.com/news/unicycive-therapeutics-announces-u-fda-120000040.html @chazzsheen3

User Image SmallCapGrowth Posted - 2 days ago

BB's Stock Haven : $UNCY announced its financial results fo... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175408653 via @Investors_Hub @chazzsheen3

User Image SmallCapGrowth Posted - 2 days ago

$UNCY Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis https://finance.yahoo.com/news/unicycive-therapeutics-announces-u-fda-120000040.html @chazzsheen3

User Image SmallCapGrowth Posted - 2 days ago

$UNCY Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update https://finance.yahoo.com/news/unicycive-announces-third-quarter-2024-121500882.html @chazzsheen3

User Image DouglasJanes2025 Posted - 2 days ago

$UNCY this is headed for 20 cents by Xmas if nothing impressive is produced before then. I’ve called the SP movement correctly so far, disagree with me at your peril.

User Image Super__Mario Posted - 2 days ago

$UNCY dead money for the next 4 months

User Image KirkHanna Posted - 2 days ago

$UNCY https://www.gurufocus.com/news/2606007/ra-capital-managements-strategic-acquisition-of-unicycive-therapeutics-shares

User Image BabyfaceMcD Posted - 3 days ago

$TNXP surprised to see SP one of my Covid favs 👀 $UNCY panned out chart looks good making notes on this one as well $AZI probably best momentum stock today looks like it will continue to climb

User Image Eliteh Posted - 3 days ago

$UNCY Anyone know if their $100 M shelf they just filed for, a preparation for the $100M in committed capital for the 3 tranches?

User Image SmallCapGrowth Posted - 3 days ago

Unicycive Therapeutics, Inc. (Nasdaq: $UNCY): Virtual Investor Conferences https://www.youtube.com/watch?v=Ycz3LAWJ8jk&t=27s

Analyst Ratings
Benchmark Speculative Buy Sep 6, 24
HC Wainwright & Co. Buy Sep 3, 24
HC Wainwright & Co. Buy Aug 15, 24
HC Wainwright & Co. Buy Jul 10, 24
HC Wainwright & Co. Buy Jun 25, 24
Benchmark Speculative Buy Jun 3, 24
Benchmark Speculative Buy May 31, 24
HC Wainwright & Co. Buy May 29, 24
HC Wainwright & Co. Buy May 14, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schiller Brigitte Director Director May 16 Buy 0.825 15,000 12,375 15,000 05/17/22